Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8J3VY)

Drug Name
Beremagene geperpavec Drug Info
Indication
Disease Entry ICD 11 Status REF
Epidermolysis bullosa EC3Z Phase 3 [1]
Cross-matching ID
TTD Drug ID
DM8J3VY

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Collagen VII (COL7A1) TTBCOKN CO7A1_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT04491604) A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously "KB103") for the Treatment of Dystrophic Epidermolysis Bullosa (DEB). U.S.National Institutes of Health.
2 Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med. 2022 Dec 15;387(24):2211-2219.